PDF herunterladen
CC BY-NC-ND 4.0 · Int Arch Otorhinolaryngol 2017; 21(04): 390-398
DOI: 10.1055/s-0036-1597665
Systematic Review
Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil

HMGB1 in the Pathogenesis of Nasal Inflammatory Diseases and its Inhibition as New Therapeutic Approach: A Review from the Literature

Luisa Maria Bellussi
1   ENT Department, University of Siena, Siena, Italy
,
Serena Cocca
1   ENT Department, University of Siena, Siena, Italy
,
Giulio Cesare Passali
2   ENT Department, Sacred Heart University, Rome, Italy
,
Desideri Passali
1   ENT Department, University of Siena, Siena, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

28. Juni 2016

31. Oktober 2016

Publikationsdatum:
04. Januar 2017 (online)

   Lizenzen und Reprints

Abstract

Introduction This study is a systematic review on recent developments about the importance of HMGB1 protein in the pathogenesis of rhino-sinusal inflammatory diseases. We also report data on the use of 18-β-glycyrrhetic acid (GA), which has been shown able to inhibit the pro-inflammatory activities of HMGB1, in young patients affected by allergic rhinitis and complaining of nasal obstruction as main symptom.

Objectives The objective of this study was to review the literature to demonstrate the importance of HMGB1 in the pathogenesis of nasal inflammatory disorders and understand whether the inhibition of this protein may be an efficacious and innovative therapeutic strategy for patients with rhino-sinusal inflammation.

Data Synthesis Authors searched for pertinent articles indexed in PubMed, Scopus, and other health journals between 2004 and 2015.

In total, the authors gathered 258 articles: 219 articles through Pubmed and 39 articles from other search engines. The search terms used were as follows: HMGB1 AND “respiratory epithelium,” “airway inflammation,” “rhinitis,” “allergic rhinitis,” “rhinosinusitis,” “nasal polyposis,” “glycyrrhetic acid,” “children.”

Conclusions Patients with severe symptoms have the highest serum levels and the highest extracellular expression of HMGB1. GA inhibits HMGB1 chemotactic and mitogenic function by a scavenger mechanism on extracellular HMGB1 accumulation stimulated by lipopolysaccharides in vitro. Treatment of allergic rhinitis with GA is not associated with local or systemic side effects in children and adults.

Keywords

rhino-sinusal inflammation - HMGB1 - allergic rhinitis - chronic rhinosinusitis - glycyrrhetic acid
 

  • References

  • 1 Turner PJ, Kemp AS. Allergic rhinitis in children. J Paediatr Child Health 2012; 48 (04) 302-310
    CrossrefPubMedGoogle Scholar
  • 2 Kemp AS. Allergic rhinitis. Paediatr Respir Rev 2009; 10 (02) 63-68
    CrossrefPubMedGoogle Scholar
  • 3 Konstantinopoulou S, Sideris GA, DelRosso LM. The Role of Co-Morbidities. Curr Probl Pediatr Adolesc Health Care 2016; 46 (01) 7-10
    CrossrefPubMedGoogle Scholar
  • 4 Gentile D, Bartholow A, Valovirta E, Scadding G, Skoner D. Current and future directions in pediatric allergic rhinitis. J Allergy Clin Immunol Pract 2013; 1 (03) 214-226 , quiz 227
    CrossrefPubMedGoogle Scholar
  • 5 Brozek JL, Bousquet J, Baena-Cagnani CE. , et al; Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126 (03) 466-476
    CrossrefPubMedGoogle Scholar
  • 6 Lunn M, Craig T. Rhinitis and sleep. Sleep Med Rev 2011; 15 (05) 293-299
    CrossrefPubMedGoogle Scholar
  • 7 Craig TJ, Sherkat A, Safaee S. Congestion and sleep impairment in allergic rhinitis. Curr Allergy Asthma Rep 2010; 10 (02) 113-121
    CrossrefPubMedGoogle Scholar
  • 8 Sardana N, Craig TJ. Congestion and sleep impairment in allergic rhinitis. Asian Pac J Allergy Immunol 2011; 29 (04) 297-306
    PubMedGoogle Scholar
  • 9 Canonica GW, Compalati E. Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies. Clin Exp Immunol 2009; 158 (03) 260-271
    CrossrefPubMedGoogle Scholar
  • 10 Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5 (04) 331-342
    CrossrefPubMedGoogle Scholar
  • 11 Wittemann B, Neuer G, Michels H, Truckenbrodt H, Bautz FA. Autoantibodies to nonhistone chromosomal proteins HMG-1 and HMG-2 in sera of patients with juvenile rheumatoid arthritis. Arthritis Rheum 1990; 33 (09) 1378-1383
    CrossrefPubMedGoogle Scholar
  • 12 Popovic K, Ek M, Espinosa A. , et al. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum 2005; 52 (11) 3639-3645
    CrossrefPubMedGoogle Scholar
  • 13 Vroling AB, Fokkens WJ, van Drunen CM. How epithelial cells detect danger: aiding the immune response. Allergy 2008; 63 (09) 1110-1123
    CrossrefPubMedGoogle Scholar
  • 14 Park JS, Svetkauskaite D, He Q. , et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279 (09) 7370-7377
    CrossrefPubMedGoogle Scholar
  • 15 Passali D, Kern E, Lei Chen R, Bellussi L. High mobility group box 1 (HMGB 1): a new protein in the pathogenesis of ENT inflammatory and infectious diseases. Acta Otorhinolaryngol Ital 2012; 32 (01) 46-47
    PubMedGoogle Scholar
  • 16 Bellussi LM, Chen L, Chen D, Passali FM, Passali D. The role of High Mobility Group Box 1 chromosomal protein in the pathogenesis of chronic sinusitis and nasal polyposis. Acta Otorhinolaryngol Ital 2012; 32 (06) 386-392
    PubMedGoogle Scholar
  • 17 Salpietro C, Cuppari C, Grasso L. , et al. Nasal high-mobility group box-1 protein in children with allergic rhinitis. Int Arch Allergy Immunol 2013; 161 (02) 116-121
    CrossrefPubMedGoogle Scholar
  • 18 Damiani V, Camaioni A, Viti C. , et al. Short-term Efficacy of Narivent® in the Treatment of Nasal Congestion. Open Med Dev J 2012; 4: 66-72
    Google Scholar
  • 19 Damiani V, Camaioni A, Viti C, Scirè AS, Morpurgo G, Gregori D. Long-term Efficacy of Narivent® in the Treatment of Nasal Congestion. Open Med Dev J 2012; 4: 73-79
    Google Scholar
  • 20 Damiani V, Vicheva D, Camaioni A. , et al. Economic Impact of Treatments for Controlling Symptoms Associated with Rhinitis: an Evaluation of Narivent® vs Standard Therapy. The Open Med Dev J 2012; 4: 61-65
    Google Scholar
  • 21 Mansi N, D'Agostino G, Scirè AS, Morpurgo G, Gregori D, Damiani V. A before-after assessment of the efficacy of Narivent® in the treatment of symptoms associated with allergic rhinitis in a pediatric population. Open Med Dev J 2012; 4: 80-86
    Google Scholar
  • 22 Damiani V, Camaioni A, Viti C, Scirè AS, Morpurgo G, Gregori D. A single-centre, before-after study of the short- and long-term efficacy of Narivent(®) in the treatment of nasal congestion. J Int Med Res 2012; 40 (05) 1931-1941
    CrossrefPubMedGoogle Scholar
  • 23 Cuppari C, Salpietro A, Grasso L. , et al. HMGB1 and allergic rhinitis in children: preliminary results after corticosteroids or glycyrrhetic acid intranasal treatment. The Child 2012; 1 (02) 1-2
    Google Scholar
  • 24 Mansi N, D'Agostino G, Scirè AS. , et al. Allergic Rhinitis in Children: A Randomized Clinical Trial Targeted at Symptoms. Indian J Otolaryngol Head Neck Surg 2014; 66 (04) 386-393
    CrossrefPubMedGoogle Scholar
  • 25 Hong SM, Cho JS, Um JY. , et al. Increased expression of high-mobility group protein B1 in chronic rhinosinusitis. Am J Rhinol Allergy 2013; 27 (04) 278-282
    CrossrefPubMedGoogle Scholar
  • 26 Bellussi LM, Iosif C, Sarafoleanu C. , et al. Are HMGB1 protein expression and secretion markers of upper airways inflammatory diseases?. J Biol Regul Homeost Agents 2013; 27 (03) 791-804
    PubMedGoogle Scholar
  • 27 Chen D, Bellussi LM, Passali D, Chen L. LPS may enhance expression and release of HMGB1 in human nasal epithelial cells in vitro. Acta Otorhinolaryngol Ital 2013; 33 (06) 398-404
    PubMedGoogle Scholar
  • 28 Ullah MA, Loh Z, Gan WJ. , et al. Receptor for advanced glycation end products and its ligand high-mobility group box-1 mediate allergic airway sensitization and airway inflammation. J Allergy Clin Immunol 2014; 134 (02) 440-450
    CrossrefPubMedGoogle Scholar
  • 29 Chen D, Mao M, Bellussi LM, Passali D, Chen L. Increase of high mobility group box chromosomal protein 1 in eosinophilic chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol 2014; 4 (06) 453-462
    CrossrefPubMedGoogle Scholar
  • 30 Paris G, Pozharskaya T, Asempa T, Lane AP. Damage-associated molecular patterns stimulate interleukin-33 expression in nasal polyp epithelial cells. Int Forum Allergy Rhinol 2014; 4 (01) 15-21
    CrossrefPubMedGoogle Scholar
  • 31 Musumeci D, Roviello GN, Montesarchio D. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacol Ther 2014; 141 (03) 347-357
    CrossrefPubMedGoogle Scholar
  • 32 Min HJ, Kim SJ, Kim TH, Chung HJ, Yoon JH, Kim CH. Level of secreted HMGB1 correlates with severity of inflammation in chronic rhinosinusitis. Laryngoscope 2015; 125 (07) E225-E230
    CrossrefPubMedGoogle Scholar
  • 33 Cavone L, Cuppari C, Manti S. , et al. Increase in the level of proinflammatory cytokine HMGB1 in nasal fluids of patients with rhinitis and its sequestration by glycyrrhizin induces eosinophils cell death. Clin Exp Otorhinolaryngol 2015; 8 (02) 123-128
    CrossrefPubMedGoogle Scholar
  • 34 Dzaman K, Szczepanski MJ, Molinska-Glura M, Krzeski A, Zagor M. Expression of the receptor for advanced glycation end products, a target for high mobility group box 1 protein, and its role in chronic recalcitrant rhinosinusitis with nasal polyps. Arch Immunol Ther Exp (Warsz) 2015; 63 (03) 223-230
    CrossrefPubMedGoogle Scholar
  • 35 Dzaman K, Zagor M, Molinska-Glura M, Krzeski A. High motility group box 1 (HMGB1) protein and its receptor for advanced glycation end products (RAGE) expression in chronic rhinosinusitis without nasal polyps. Folia Histochem Cytobiol 2015; 53 (01) 70-78
    CrossrefPubMedGoogle Scholar
  • 36 Bousquet J, Khaltaev N, Cruz AA. , et al; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl. 86) 8-160
    CrossrefPubMedGoogle Scholar
  • 37 Passàli D, Salerni L, Passàli GC, Passàli FM, Bellussi L. Nasal decongestants in the treatment of chronic nasal obstruction: efficacy and safety of use. Expert Opin Drug Saf 2006; 5 (06) 783-790
    CrossrefPubMedGoogle Scholar
  • 38 Baena-Cagnani CE. Safety and tolerability of treatments for allergic rhinitis in children. Drug Saf 2004; 27 (12) 883-898
    CrossrefPubMedGoogle Scholar
  • 39 Storms W. Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction. Expert Opin Pharmacother 2007; 8 (13) 2173-2187
    CrossrefPubMedGoogle Scholar
  • 40 Howland III WC. Fluticasone propionate: topical or systemic effects?. Clin Exp Allergy 1996; 26 (Suppl. 03) 18-22
    PubMedGoogle Scholar
  • 41 Howland III WC, Hampel Jr FC, Martin BG, Ratner PH, van Bavel JH, Field EA. The efficacy of fluticasone propionate aqueous nasal spray for allergic rhinitis and its relationship to topical effects. Clin Ther 1996; 18 (06) 1106-1117
    CrossrefPubMedGoogle Scholar
  • 42 Mener DJ, Shargorodsky J, Varadhan R, Lin SY. Topical intranasal corticosteroids and growth velocity in children: a meta-analysis. Int Forum Allergy Rhinol 2015; 5 (02) 95-103
    CrossrefPubMedGoogle Scholar
  • 43 Ploeger B, Mensinga T, Sips A, Seinen W, Meulenbelt J, DeJongh J. The pharmacokinetics of glycyrrhizic acid evaluated by physiologically based pharmacokinetic modeling. Drug Metab Rev 2001; 33 (02) 125-147
    CrossrefPubMedGoogle Scholar
  • 44 Saeedi M, Morteza-Semnani K, Ghoreishi MR. The treatment of atopic dermatitis with licorice gel. J Dermatolog Treat 2003; 14 (03) 153-157
    CrossrefPubMedGoogle Scholar
  • 45 Cosmetic Ingredient Review Expert Panel. Final report on the safety assessment of Glycyrrhetinic Acid, Potassium Glycyrrhetinate, Disodium Succinoyl Glycyrrhetinate, Glyceryl Glycyrrhetinate, Glycyrrhetinyl Stearate, Stearyl Glycyrrhetinate, Glycyrrhizic Acid, Ammonium Glycyrrhizate, Dipotassium Glycyrrhizate, Disodium Glycyrrhizate, Trisodium Glycyrrhizate, Methyl Glycyrrhizate, and Potassium Glycyrrhizinate. Int J Toxicol 2007; 26 (02) (Suppl. 02) 79-112
    PubMedGoogle Scholar
  • 46 Yang H, Wang H, Czura CJ, Tracey KJ. HMGB1 as a cytokine and therapeutic target. J Endotoxin Res 2002; 8 (06) 469-472
    CrossrefPubMedGoogle Scholar
  • 47 Mollica L, De Marchis F, Spitaleri A. , et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 2007; 14 (04) 431-441
    CrossrefPubMedGoogle Scholar
  • 48 van Rossum TG, Vulto AG, Hop WC, Brouwer JT, Niesters HG, Schalm SW. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol 1999; 14 (11) 1093-1099
    CrossrefPubMedGoogle Scholar
  • 49 Chen S, Wang Y, Gong G, Chen J, Niu Y, Kong W. Ethyl pyruvate attenuates murine allergic rhinitis partly by decreasing high mobility group box 1 release. Exp Biol Med (Maywood) 2015; 240 (11) 1490-1499
    CrossrefPubMedGoogle Scholar